Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Tax Strategy Demystified: A Q&A With Ernst & Young

Executive Summary

Several of this year’s biggest biopharma M&A deals provide significant tax benefits. “The Pink Sheet” brushes up on how multinational companies are managing tax considerations and examines more closely the core taxation issues for the industry.

Advertisement

Related Content

Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Sen. Baucus Still Has Ambitious Agenda: Tax Reform, Deficit Reduction, ACA
Pharmas Among Biggest Cash Hoarders, Moody’s Finds
Deals Of The Week: Alnylam/The Medicines Co., Inspiration/Cangene, Pfizer/OxOnc

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055648

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel